Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Bristol-Myers Squibb Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (59)
Cancellation by sponsor (41)
Australian Public Assessment Report (AusPAR) (31)
Prescription medicine registration (26)
Prescription medicine evaluation (7)
Designation or determination (5)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (2)

Date

2024 (12)
2023 (6)
2022 (18)
2021 (9)
2020 (15)
2019 (4)
2018 (23)
2017 (18)
2016 (5)
2015 (14)
2014 (4)
2013 (7)
2012 (5)
2011 (10)
2010 (3)
2009 (3)
2007 (12)
2004 (1)
1993 (2)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

173 result(s) found, displaying 81 to 90

EVOTAZ atazanavir/cobicistat 300 mg/150 mg film coated tablets bottle (229476)

23 September 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EVOTAZ atazanavir/cobicistat 300 mg/150 mg film coated tablets bottle.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

23 April 2018

Prescription medicine registration

Active ingredients: nivolumab.
ORENCIA abatacept (rch) 125 mg single dose ClickJect prefilled autoinjector (236039)

17 June 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ORENCIA abatacept (rch) 125 mg single dose ClickJect prefilled autoinjector.
MODECATE fluphenazine decanoate 12.5mg/0.5mL injection ampoule Cancelled under s30(1)(c)

21 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MODECATE fluphenazine decanoate 25mg/1mL injection ampoule Cancelled under s30(1)(c)

21 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MODECATE fluphenazine decanoate 50mg/2mL injection ampoule Cancelled under s30(1)(c)

21 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
BARACLUDE entecavir monohydrate 0.05mg/mL oral liquid solution bottle Cancelled under s30(1)(c)

21 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
VIDEX EC didanosine 200mg capsule bottle Cancelled under Section 30(1)(c) of the Act

9 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
VIDEX EC didanosine 250mg capsule bottle Cancelled under Section 30(1)(c) of the Act

9 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
VIDEX EC didanosine 400mg capsule bottle Cancelled under Section 30(1)(c) of the Act

9 March 2018

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.